ORION-LVAD-1: ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices
Study Details
Study Description
Brief Summary
This is a open-label, uncontrolled, monocenter, phase IV study. The aim of this study is to detect AEs or SAEs with a relative frequency of at least 11.5% in LVAD patients with iron deficiency anemia treated with oral ferric maltol for 12 weeks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Ferric maltol 30 mg (Feraccru®) Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks |
Drug: Ferric maltol 30 mg (Feraccru®)
Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
|
Outcome Measures
Primary Outcome Measures
- To detect AEs and SAEs with a relative frequency of at least 11.5% in LVAD patients with iron deficiency anemia treated with oral ferric maltol for 12 weeks [baseline to week 12]
Secondary Outcome Measures
- Change in hemoglobin level from baseline to week 12 [baseline to week 12]
- Change in hemoglobin level from baseline to week 6 [baseline to week 6]
- Change in serum ferritin levels and transferrin saturation from baseline to week 6 [baseline to week 6]
- Change in serum ferritin levels and transferrin saturation from baseline to week 12 [baseline to week 12]
- Change in 6 min walking distance from baseline to week 12 [baseline to week 12]
- Change in serum NT-proBNP from baseline to weeks 6 [baseline to weeks 6]
- Change in serum NT-proBNP from baseline to weeks 12 [baseline to weeks 12]
- Change in echocardiographic markers of right ventricular function (right atrial area, right ventricular diameter, fractional area change, tricuspid annular plane systolic excursion) [change from baseline to week 12]
- Change in echocardiographic markers of left ventricular function (left ventricular ejection fraction, left atrial area, left ventricular diameter, fractional area change, tricuspid annular plane systolic excursion) [change from baseline to week 12]
- Liver: Change in Albumin, ALT, AST and Bilirubin from baseline to week 12 [from baseline to week 12]
- Liver: Change in Albumin, ALT, AST and Bilirubin from baseline to week 6 [from baseline to week 6]
- Kidney: Change in Creatinine (+GFR) and Urea from baseline to week 12 [from baseline to week 12]
- Kidney: Change in Creatinine (+GFR) and Urea from baseline to week 6 [from baseline to week 6]
- Change in NYHA from baseline to week 12 [from baseline to week 12]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed written informed consent prior to any study-related procedure and willingness to comply with treatment and follow-up procedures
-
Male and female patients ≥18 years at day of inclusion
-
Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial
-
Patients that have an LVAD implanted for chronic heart failure and which are clinically stable for at least 6 months after LVAD implantation in the opinion of the investigator
-
6 min walk distance >50 m
-
Mild-to-moderate iron-deficiency anemia as defined by a hemoglobin concentration ≥7 g/dl and <12 g/dl in females or ≥8 g/dl and <13 g/dl in males, and serum ferritin <100 µg/l, or 100-300 µg/l and transferrin saturation <20% at screening
-
Women of childbearing potential must:
Have a negative pregnancy test at screening Agree to use reliable methods of contraception during the course of the study
Exclusion Criteria:
-
Active hematological disorders other than iron-deficiency anemia
-
Other medical condition that according to the investigator's assessment is causing or contributing to anemia
-
Active malignancy
-
Active infectious disease
-
Active bleeding
-
Severe renal insufficiency (requiring dialysis)
-
Severe liver injury as indicated by serum aminotransferases >3 x upper limit of normal or bilirubin levels >50 µmol/l
-
Ongoing oral or intravenous iron supplementation
-
Concomitant erythropoietin medication
-
Pregnancy or lactation period
-
Subject has received any investigational medication or any investigational devices within 30 days prior to the first dose of study medication or is actively participating in any investigational drug/ devices trial, or is scheduled to receive investigational drug/devices during the course of the study.
-
Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal product
-
Known haemochromatosis or other iron overload syndromes
-
Patients who have been receiving repeated (>1) blood transfusions during the past 6 months
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medizinische Hochschule Hannover, Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie (HTTG) | Hannover | Germany | 30625 |
Sponsors and Collaborators
- Hannover Medical School
- Shields, Shields and Associates
Investigators
- Principal Investigator: Jan Schmitto, Prof. MD, Hannover Medical School
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ORION-LVAD-1